Hintzsche Jennifer D, Yoo Minjae, Kim Jihye, Amato Carol M, Robinson William A, Tan Aik Choon
Division of Medical Oncology, Department of Medicine, Translational Bioinformatics and Cancer Systems Biology Laboratory, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Division of Medical Oncology, Department of Medicine, Robinson Melanoma Laboratory, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
BMC Med Genomics. 2018 Apr 20;11(Suppl 2):26. doi: 10.1186/s12920-018-0350-1.
With the advancement of next generation sequencing technology, researchers are now able to identify important variants and structural changes in DNA and RNA in cancer patient samples. With this information, we can now correlate specific variants and/or structural changes with actionable therapeutics known to inhibit these variants. We introduce the creation of the IMPACT Web Portal, a new online resource that connects molecular profiles of tumors to approved drugs, investigational therapeutics and pharmacogenetics associated drugs.
IMPACT Web Portal contains a total of 776 drugs connected to 1326 target genes and 435 target variants, fusion, and copy number alterations. The online IMPACT Web Portal allows users to search for various genetic alterations and connects them to three levels of actionable therapeutics. The results are categorized into 3 levels: Level 1 contains approved drugs separated into two groups; Level 1A contains approved drugs with variant specific information while Level 1B contains approved drugs with gene level information. Level 2 contains drugs currently in oncology clinical trials. Level 3 provides pharmacogenetic associations between approved drugs and genes.
IMPACT Web Portal allows for sequencing data to be linked to actionable therapeutics for translational and drug repurposing research. The IMPACT Web Portal online resource allows users to query genes and variants to approved and investigational drugs. We envision that this resource will be a valuable database for personalized medicine and drug repurposing. IMPACT Web Portal is freely available for non-commercial use at http://tanlab.ucdenver.edu/IMPACT .
随着下一代测序技术的进步，研究人员现在能够识别癌症患者样本中DNA和RNA的重要变异及结构变化。有了这些信息，我们现在可以将特定变异和/或结构变化与已知可抑制这些变异的可操作治疗方法相关联。我们介绍了IMPACT网络门户的创建，这是一个新的在线资源，它将肿瘤的分子图谱与已批准的药物、研究性治疗方法和药物遗传学相关药物联系起来。
IMPACT网络门户总共包含776种与1326个靶基因以及435个靶变异、融合和拷贝数改变相关的药物。在线IMPACT网络门户允许用户搜索各种基因改变，并将它们与三个可操作治疗水平联系起来。结果分为三个级别：1级包含分为两组的已批准药物；1A级包含具有变异特异性信息的已批准药物，而1B级包含具有基因水平信息的已批准药物。2级包含目前正在进行肿瘤学临床试验的药物。3级提供已批准药物与基因之间的药物遗传学关联。
IMPACT网络门户允许将测序数据与用于转化研究和药物再利用研究的可操作治疗方法相联系。IMPACT网络门户在线资源允许用户查询与已批准和研究性药物相关的基因和变异。我们设想这个资源将成为个性化医疗和药物再利用的宝贵数据库。IMPACT网络门户可在http://tanlab.ucdenver.edu/IMPACT上免费用于非商业用途。
